MRK 📈 Merck & - Overview

Merck & Co., Inc. is a multinational healthcare company that operates globally, with a diverse portfolio of products and services. The company is divided into two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment is responsible for developing, manufacturing, and marketing a wide range of human health pharmaceutical products, including treatments for oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes. Some of the notable brands under this segment include Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia, which cater to various therapeutic areas. Additionally, the company offers a range of vaccine products, such as Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta, which provide preventive care for pediatric, adolescent, and adult populations.

The Animal Health segment, on the other hand, focuses on discovering, developing, manufacturing, and marketing veterinary pharmaceuticals, vaccines, and health management solutions and services. This segment also offers digitally connected identification, traceability, and monitoring products, which enable animal healthcare professionals to provide better care and management. The company has a strong pipeline of products and collaborations, including development and commercialization agreements with other pharmaceutical companies, such as Daiichi Sankyo and AstraZeneca PLC. For instance, Merck & Co., Inc. has partnered with Daiichi Sankyo to develop and commercialize three deruxtecan ADC candidates, including patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan, which are being investigated for the treatment of multiple solid tumors. The company has also collaborated with AstraZeneca PLC to co-develop and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, as well as Koselugo for multiple indications.

Merck & Co., Inc. has a long history, dating back to 1891, and is headquartered in Rahway, New Jersey. The company has a strong commitment to research and development, with a focus on developing innovative products and solutions that address unmet medical needs. In addition to its partnerships with other pharmaceutical companies, Merck & Co., Inc. has also collaborated with other organizations, such as Eisai Co., Ltd., Bayer AG, Ridgeback Biotherapeutics LP, and Moderna, Inc. The company's common stock is listed on the New York Stock Exchange (NYSE) under the ticker symbol MRK, and its ISIN is US58933Y1055. As a leading player in the pharmaceutical industry, Merck & Co., Inc. is well-positioned to continue making significant contributions to the field of healthcare, with a strong pipeline of products and a commitment to innovation and excellence.